Bay City Capital

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

SemBioSys Genetics Inc., a Canadian biotechnology company, announced today that it has signed a feasibility agreement with Dow AgroSciences LLC, of Indianapolis, Indiana, for the Stratosome(TM) Biologics System and its application to animal health biologics. Under the terms of the agreement, SemBioSys and Dow AgroSciences will engage in collaborative research with the aim of determining if the Stratosome(TM) Biologics System can enable the commercialisation of a Dow AgroSciences plant-made vaccine. Under the terms of the agreement, SemBioSys will receive upfront and milestone payments. Further terms of the agreement were not disclosed. " We believe that our Stratosome(TM) Biologics System, with its economic and functional benefits, makes it an outstanding platform for animal health products. We are extremely pleased to be working with Dow AgroSciences in developing their vaccine," said Andrew Baum, president and CEO of SemBioSys. "We are very pleased to be working with SemBioSys in evaluating the Stratosome(TM) technology and its application to plant-made biologics for the animal health industry," stated Butch Mercer, Global Business Leader, Animal Health and Nutrition for Dow AgroSciences This is the third funded development agreement announced by SemBioSys in the last six months. In December, SemBioSys announced that it had executed a development agreement with Martek Biosciences Corporation (Nasdaq: MATK) to co- develop value-added specialty oil products (DHA containing safflower oil) with potential pharmaceutical and nutraceutical applications. In February, SemBioSys announced that it had entered into an agreement with Syngenta for access to SemBioSys' proprietary oilbody based Stratosome(TM) Biologics and StratoCapture(TM) Purification Systems for the development of Syngenta's biologic products. About SemBioSys Genetics Inc. (www.sembiosys.com) Calgary, Alberta-based SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development of therapeutic proteins and oils using its proprietary oilbody-based technology - the Stratosome(TM) Biologics System. Spun out of the University of Calgary in 1994, the company's investors include Bay City Capital, Dow AgroSciences Canada, Inc., Ventures West Management Inc., BDC Venture Capital, University Technologies International Inc., RBC Capital Partners and Maurice Moloney Ph.D. scientific founder and chief scientific officer. In addition to these investors, SemBioSys has received repayable contributions of CAD$5.5MM from Technology Partnerships Canada, an agency of Industry Canada, and CAD$4.9MM from AVAC Ltd. SemBioSys has partnerships with Syngenta Participations AG and Martek Biosciences for the use of its Stratosome(TM) technology for the development of therapeutic products.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

KBP Biosciences is a biotechnology research and development organization focused on creating innovative therapies for unmet medical needs, particularly in the fields of cardiovascular, respiratory, inflammatory, and autoimmune diseases. The company is dedicated to the research, development, and commercialization of novel medicines, leveraging new drug development ideas alongside its own medicinal chemistry expertise. With a strong emphasis on clinical development and regulatory compliance, KBP Biosciences aims to empower healthcare providers by offering effective treatments to improve patient outcomes in areas where existing therapeutic options are limited.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the pressing issue of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound that is currently undergoing Phase III clinical trials. Sulopenem is designed for both oral and intravenous use and aims to treat various serious infections, including uncomplicated and complicated urinary tract infections as well as complicated intra-abdominal infections. The company’s mission is to significantly improve the lives of patients affected by serious and life-threatening diseases by providing effective solutions to antibiotic resistance.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is primarily engaged in the clinical study of VTS-270 for the treatment of Niemann-Pick Disease Type C (NPC) and is also involved in the pre-clinical discovery and development of additional novel drugs for NPC and other lysosomal storage diseases. Vtesse operates as a subsidiary of Sucampo Pharmaceuticals, Inc. and is recognized as the first spin-out from Cydan Development, Inc., an orphan-drug accelerator. The company collaborates with the National Institutes of Health (NIH) to advance its clinical programs and is supported by a seasoned management team with extensive experience in drug development. Vtesse's initiatives aim not only to provide innovative therapies but also to offer resources and support for patients and families affected by NPC and related conditions.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of innovative antibody-based biopharmaceuticals. The company specializes in bispecific antibody therapeutics, utilizing its proprietary Oligoclonics technology to produce a unique class of human antibodies. This technology enables the generation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Merus is also advancing its full-length human multispecific antibody therapeutics, known as Biclonics. The company has a diverse pipeline of product candidates, including MCLA-128, MCLA-117, and MCLA-158, among others, all designed to address various challenges in immuno-oncology.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is primarily engaged in the clinical study of VTS-270 for the treatment of Niemann-Pick Disease Type C (NPC) and is also involved in the pre-clinical discovery and development of additional novel drugs for NPC and other lysosomal storage diseases. Vtesse operates as a subsidiary of Sucampo Pharmaceuticals, Inc. and is recognized as the first spin-out from Cydan Development, Inc., an orphan-drug accelerator. The company collaborates with the National Institutes of Health (NIH) to advance its clinical programs and is supported by a seasoned management team with extensive experience in drug development. Vtesse's initiatives aim not only to provide innovative therapies but also to offer resources and support for patients and families affected by NPC and related conditions.

Interleukin Genetics, Inc. is a company specializing in personalized health through the development of genetic tests aimed at enhancing individual wellness. The organization focuses on two primary areas: the provision of genetic test products for personal health improvement and research and development efforts that create tests linked to partners’ products for medical and dental markets. Their genetic testing technology provides clear insights into wellness, offering personalized guidance on diet and exercise choices, which empowers individuals to take proactive steps in managing their health. Through partnerships and direct sales channels, Interleukin Genetics aims to contribute to the growing personalized health market by enabling individuals to make informed decisions about their health and wellness.

SynGen Inc. is a biotechnology company that specializes in the development, design, and manufacturing of innovative cell separation tools and accessories aimed at the recovery of target cells while depleting contaminating cells. Founded in 2007 and headquartered in Sacramento, California, with an additional location in Runcorn, United Kingdom, SynGen offers a range of medical devices, including the SynGenX-1000 and SynGenX-2000 Systems, which are closed sterile processing systems designed for the isolation of stem and progenitor cells and the preparation of platelet-rich plasma, respectively. The company also provides laboratory solutions such as the SynGenX-Lab System for cell extraction and the CryoPRO Workstation for cryopreservation. Additionally, SynGen develops software like SynGen DataTrak for data management in clinical and manufacturing environments. Its products are utilized in diagnostic, research, and clinical processes, contributing significantly to the field of regenerative medicine.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in West Conshohocken, Pennsylvania, that specializes in developing therapeutics for cardiovascular, metabolic, and liver diseases. The company’s lead product, MGL-3196, is an orally administered small-molecule, liver-directed thyroid hormone receptor (THR) ß-selective agonist, currently in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Additionally, Madrigal is advancing MGL-3745, another THR-ß-selective small molecule, which is in preclinical trials aimed at addressing NASH and hyperlipidemia. The company has established a research and development agreement with Hoffmann-La Roche to support its efforts in utilizing and commercializing various licensed products. Through its innovative approach, Madrigal Pharmaceuticals aims to address both niche and prevalent conditions, including diabetes and dyslipidemia.

Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.

Galecto is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to address severe diseases, particularly fibrosis and cancer. Established in 2011, Galecto builds on over a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company's lead product candidate, GB0139, is an inhaled galectin-3 inhibitor specifically designed for treating severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. Additionally, Galecto is advancing GB1211, an oral selective galectin-3 inhibitor aimed at addressing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto leverages its unique therapeutic platform to target the underlying biological processes associated with fibrosis and related diseases.

PharmAkea Therapeutics, headquartered in San Diego, California, is a biopharmaceutical company focused on developing high-quality small molecule drug candidates targeting proteins associated with fibroproliferative diseases. The company aims to accelerate patient access to effective treatments by creating innovative therapeutics for cancer and fibrotic disorders, enabling quicker initiation of therapy and potentially improving treatment outcomes.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of innovative antibody-based biopharmaceuticals. The company specializes in bispecific antibody therapeutics, utilizing its proprietary Oligoclonics technology to produce a unique class of human antibodies. This technology enables the generation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Merus is also advancing its full-length human multispecific antibody therapeutics, known as Biclonics. The company has a diverse pipeline of product candidates, including MCLA-128, MCLA-117, and MCLA-158, among others, all designed to address various challenges in immuno-oncology.

Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The company identifies and de-risks compounds that hold therapeutic and commercial potential, employing a rigorous process to generate data that supports both development pathways and the formation of new companies. With a team that boasts deep expertise in drug development and strong relationships within academia and patient advocacy, Cydan accelerates therapies through various stages, including clinical, regulatory, and commercial development. By facilitating the creation of effective treatments, Cydan aims to improve the lives of patients and families affected by rare diseases.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.

TRIA Beauty, Inc. is a developer and marketer of light-based medical devices aimed at the consumer market, specializing in beauty and skincare solutions. Founded in 2003 and headquartered in Dublin, California, the company offers a range of innovative products including a hand-held, cordless diode laser for hair removal, a Skin Perfecting Blue Light device for acne treatment, a Skin Rejuvenating Laser for anti-aging purposes, and an Age-Defying Eye Wrinkle Correcting Laser. These devices utilize advanced light technology, which is preferred by dermatologists for effective skincare treatments, allowing users to achieve professional results at home. TRIA Beauty products are available through its e-commerce platform and various indirect sales channels, including retail outlets, television, and physician offices. The company serves a global market, reaching customers in the United States, Japan, South Korea, Canada, the United Kingdom, Germany, and Spain.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Interleukin Genetics, Inc. is a company specializing in personalized health through the development of genetic tests aimed at enhancing individual wellness. The organization focuses on two primary areas: the provision of genetic test products for personal health improvement and research and development efforts that create tests linked to partners’ products for medical and dental markets. Their genetic testing technology provides clear insights into wellness, offering personalized guidance on diet and exercise choices, which empowers individuals to take proactive steps in managing their health. Through partnerships and direct sales channels, Interleukin Genetics aims to contribute to the growing personalized health market by enabling individuals to make informed decisions about their health and wellness.

Nabsys is a biotechnology company based in Providence, Rhode Island, that specializes in semiconductor-based tools for genomic analysis. Founded in 2004, Nabsys has developed an innovative electronic mapping platform that offers a comprehensive view of the human genome. The company's technology utilizes solid-state nano-detectors to analyze entire genomes in large fragments, exceeding 100,000 base pairs and processing at speeds greater than one million base pairs per second. This advanced capability allows researchers to effectively examine structural variations and genome assembly, facilitating the confirmation of genetic variants. Nabsys has received recognition for its contributions to DNA analysis, including a “1000 Genome” award from the National Human Genome Research Institute.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Ascendancy Healthcare offers a novel approach to the commercialization of products in China and related emerging markets by providing companies with customized partnership solutions tailored to their individual needs for doing business in these regions. Ascendancy enables product entry and optimizes growth by providing clinical, regulatory and commercial expertise and oversight along with funding to bring products from the United States, Europe and/or Japan to China and other high-growth Asian markets. Ascendancy is privately held and its investors include Bay City Capital and IndUS Growth Partners.

GenturaDx is a molecular diagnostics company that specializes in making multiplexed molecular testing accessible and practical for laboratories. The company's innovative IDbox™ system utilizes a single-use cassette that addresses traditional challenges related to cost, automation, and performance, thereby enabling in-house lab testing that delivers actionable results. GenturaDx develops automated instruments designed for use in hospitals and by patients both in the United States and internationally. Its self-contained diagnostics platform integrates sample preparation with real-time PCR amplification and detection, providing clinicians with valuable tools for identifying various infectious diseases. By streamlining the diagnostic process, GenturaDx aims to enhance the clinical benefits of molecular diagnostics for healthcare providers and their patients.

SynGen Inc. is a biotechnology company that specializes in the development, design, and manufacturing of innovative cell separation tools and accessories aimed at the recovery of target cells while depleting contaminating cells. Founded in 2007 and headquartered in Sacramento, California, with an additional location in Runcorn, United Kingdom, SynGen offers a range of medical devices, including the SynGenX-1000 and SynGenX-2000 Systems, which are closed sterile processing systems designed for the isolation of stem and progenitor cells and the preparation of platelet-rich plasma, respectively. The company also provides laboratory solutions such as the SynGenX-Lab System for cell extraction and the CryoPRO Workstation for cryopreservation. Additionally, SynGen develops software like SynGen DataTrak for data management in clinical and manufacturing environments. Its products are utilized in diagnostic, research, and clinical processes, contributing significantly to the field of regenerative medicine.

ThermoGenesis Holdings develops and markets automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. The company offers a range of solutions for clinical biobanking, point-of-care applications, and automation in immuno-oncology. Key products include the AXP Automated Cell Separation System for isolating stem cells from umbilical cord blood, the BioArchive Automated Cryopreservation System for cryogenic storage, the PXP Point-of-Care System for processing autologous stem cells at surgical centers or clinics, and the CAR-TXpress platform for streamlining CAR-T immunotherapy manufacturing. Additionally, ThermoGenesis provides X-Series products for various cell purification tasks and the AR-TXpress Platform for large-scale cellular processing. Founded in 1986 and headquartered in Rancho Cordova, California, the company was formerly known as Cesca Therapeutics Inc.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

NextWave Pharmaceuticals is a Cupertino, California-based pharmaceutical company that specializes in the development and commercialization of innovative products utilizing proprietary drug delivery technology. The company is primarily focused on creating once-daily liquid medications aimed at treating attention deficit/hyperactivity disorder (ADHD). By leveraging its unique drug delivery systems, NextWave Pharmaceuticals enables healthcare providers to effectively address various disorders related to the central nervous system, enhancing treatment options for patients.

IDEV Technologies is an emerging growth medical device company that specializes in the development of innovative products for endovascular and interventional applications, particularly within interventional radiology, gastroenterology, vascular surgery, and cardiology. The company markets its flagship product, SUPERA, a self-expanding nitinol stent designed with a patented interwoven structure that enhances flexibility, radial strength, and resistance to kinking and crushing compared to competing stents. SUPERA is approved for treating biliary strictures in the United States and is currently undergoing clinical evaluation in the SUPERB IDE trial to assess its safety and efficacy for use in the superficial femoral artery.

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Ion Torrent, a wholly-owned subsidiary of [Life Technologies](/organization/life-technologies), has pioneered an entirely new approach to sequencing that enables a direct connection between chemical and digital information. Ion Torrent™ technology doesn't use light—it's the first commercial PostLight™ sequencing technology. Instead, Ion Torrent marries simple chemistry to incredibly powerful, proven semiconductor technology—it's Watson meets Moore. The result is a sequencing system that is simpler, faster, more cost effective and scalable than any other technology available. The company's goal is to democratize sequencing and make this critical technology available to every lab.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of innovative antibody-based biopharmaceuticals. The company specializes in bispecific antibody therapeutics, utilizing its proprietary Oligoclonics technology to produce a unique class of human antibodies. This technology enables the generation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Merus is also advancing its full-length human multispecific antibody therapeutics, known as Biclonics. The company has a diverse pipeline of product candidates, including MCLA-128, MCLA-117, and MCLA-158, among others, all designed to address various challenges in immuno-oncology.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Calypso Medical Technologies is a Seattle-based medical device company that specializes in real-time localization technology for tumor tracking. Its proprietary system employs miniaturized implanted devices, known as Beacon electromagnetic transponders, to continuously and accurately monitor the location of tumors. This innovative approach aims to enhance the precision and management of radiation therapy delivery, particularly for body-wide cancers commonly treated with this method. The company's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed. Calypso Medical has established strategic partnerships with major industry players, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

Hyperion Therapeutics, Inc. is a biopharmaceutical company based in Brisbane, California, focused on developing and commercializing therapies for orphan diseases. The company specializes in treatments for urea cycle disorders (UCD), offering products such as RAVICTI, a nitrogen-binding agent used for the chronic management of UCD in both adults and pediatric patients. In addition to RAVICTI, Hyperion provides BUPHENYL and AMMONAPS for the treatment of specific UCD subtypes. The company is also exploring the application of glycerol phenylbutyrate, the active ingredient in RAVICTI, for the treatment of hepatic encephalopathy. Founded in 2006, Hyperion Therapeutics aims to address the needs of underserved patient populations through its innovative therapeutic developments.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate, vecabrutinib, is a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. Additionally, Sunesis is advancing SNS-510, which is in preclinical studies for various tumor types, alongside partnered programs such as TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer quinolone derivative. The company has established collaborations, including an agreement with Biogen Idec MA, Inc. for small molecule BTK inhibitors and a licensing agreement with Takeda Pharmaceutical Company Limited for preclinical PDK1 inhibitors. Founded in 1998 and headquartered in South San Francisco, California, Sunesis Pharmaceuticals is committed to innovative approaches in the ongoing fight against cancer.

Via Pharmaceuticals is a biotechnology company dedicated to developing novel therapies for cardiovascular diseases. Its primary focus lies in creating a pipeline of small-molecule drugs designed to reduce inflammation within blood vessel walls, addressing a significant unmet medical need and potentially preventing complications such as heart attacks and strokes. Currently, Via Pharmaceuticals operates at the development stage, concentrating its efforts on advancing its drug candidates through clinical trials.

Accriva Diagnostics is a San Diego-based company that specializes in developing near patient testing systems and advanced diagnostic solutions, primarily focusing on point-of-care cardiovascular diagnostics. Founded in 2009, the company offers a diverse range of products designed to provide timely and precise information for improved treatment outcomes. Its product lineup includes compact immunoassay analyzers, hematology analyzers, high sensitivity immunoassay analyzers, and clinical chemistry analyzers. Additionally, Accriva manufactures devices such as the Avoximeter whole blood oximeter and co-oximeter, the HemoChron Response whole blood coagulation system, and various devices for measuring blood coagulation and platelet response. These products cater to hospitals and critical care settings, enhancing patient care through efficient diagnostic capabilities.

Cadence Pharmaceuticals is a biopharmaceutical company that specializes in the in-licensing, development, and commercialization of proprietary product candidates primarily for hospital use. The company focuses on innovative therapeutic solutions, notably its investigational product candidate, OFIRMEV, which is an intravenous formulation of acetaminophen designed for managing pain and reducing fever in both adults and children. Cadence is committed to addressing unmet medical needs within the hospital setting by providing effective treatment options.

Vivaldi Biosciences is a clinical-stage biotechnology company focused on developing live attenuated influenza vaccines (LAIVs) for both seasonal and pandemic influenza. Founded in 2006, the company is based in Fort Collins, Colorado. Vivaldi's portfolio includes deltaFLU, an advanced self-adjuvanting influenza vaccine administered as a nasal spray. Additionally, the company is engaged in developing therapeutics through a small molecule program targeting the NS1 protein of influenza.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

NuPathe Inc., a Pennsylvania-based specialty pharmaceutical company, specializes in developing and commercializing branded therapeutics for neurological and psychiatric disorders. Its primary product, Zecuity, is a transdermal patch used for acute migraine treatment. NuPathe's pipeline includes NP201, a long-acting treatment for Parkinson's disease, and NP202, a long-term solution for schizophrenia and bipolar disorder, both leveraging its biodegradable implant technology. The company, founded in 2005, operates as a subsidiary of Teva Pharmaceutical Industries Limited and is actively seeking partnerships to expand its global reach.

IDEV Technologies is an emerging growth medical device company that specializes in the development of innovative products for endovascular and interventional applications, particularly within interventional radiology, gastroenterology, vascular surgery, and cardiology. The company markets its flagship product, SUPERA, a self-expanding nitinol stent designed with a patented interwoven structure that enhances flexibility, radial strength, and resistance to kinking and crushing compared to competing stents. SUPERA is approved for treating biliary strictures in the United States and is currently undergoing clinical evaluation in the SUPERB IDE trial to assess its safety and efficacy for use in the superficial femoral artery.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

Cadence Pharmaceuticals is a biopharmaceutical company that specializes in the in-licensing, development, and commercialization of proprietary product candidates primarily for hospital use. The company focuses on innovative therapeutic solutions, notably its investigational product candidate, OFIRMEV, which is an intravenous formulation of acetaminophen designed for managing pain and reducing fever in both adults and children. Cadence is committed to addressing unmet medical needs within the hospital setting by providing effective treatment options.

Aragon Surgical, Inc. is a privately owned company established in 2005, focused on creating innovative surgical products aimed at enhancing patient safety and reducing operative time. The company collaborates with various surgeons to identify opportunities for improving surgical performance. Its product line includes surgical instruments and implants specifically designed to assist gynecologic surgeons, general surgeons, and surgical specialists in performing both laparoscopic and open surgical procedures. Through its commitment to advancing surgical techniques, Aragon Surgical seeks to contribute to improved outcomes for patients and healthcare providers alike.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics—products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Francisco, California, focused on the discovery and development of small-molecule antiviral therapeutics for viral infections, particularly hepatitis C virus (HCV) and HIV. Founded in 2006, the company is dedicated to creating innovative therapies, including pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride, which target specific proteins of the HCV. Presidio's antiviral therapeutics are designed for daily oral dosing and can be used in combination with other antiviral treatments to enhance efficacy and combat viral resistance. Through its efforts, Presidio aims to provide effective drug therapies to patients dealing with various strains of hepatitis.

Vivaldi Biosciences is a clinical-stage biotechnology company focused on developing live attenuated influenza vaccines (LAIVs) for both seasonal and pandemic influenza. Founded in 2006, the company is based in Fort Collins, Colorado. Vivaldi's portfolio includes deltaFLU, an advanced self-adjuvanting influenza vaccine administered as a nasal spray. Additionally, the company is engaged in developing therapeutics through a small molecule program targeting the NS1 protein of influenza.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

NBI Development is an implantable medical device company focused on the development of novel neuromodulation therapies. The company develops neuromodulation, the use of electrical impulses to manage activity in the nervous system.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

NuPathe Inc., a Pennsylvania-based specialty pharmaceutical company, specializes in developing and commercializing branded therapeutics for neurological and psychiatric disorders. Its primary product, Zecuity, is a transdermal patch used for acute migraine treatment. NuPathe's pipeline includes NP201, a long-acting treatment for Parkinson's disease, and NP202, a long-term solution for schizophrenia and bipolar disorder, both leveraging its biodegradable implant technology. The company, founded in 2005, operates as a subsidiary of Teva Pharmaceutical Industries Limited and is actively seeking partnerships to expand its global reach.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer.

Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Radiant Medical is a private medical device company based in Redwood City, California, founded in 1999. The company specializes in endovascular temperature therapy, focusing on innovative solutions for the treatment of heart, brain, and kidney disorders. Radiant Medical's primary product is a comprehensive system that includes a single-use central venous heat exchange balloon catheter, a heat exchange cassette, a microprocessor-driven controller, and an integrated temperature sensor. This system enables healthcare providers to safely and efficiently control patient core body temperature, allowing for rapid cooling, maintenance, and warming as needed during medical procedures.

Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

Calypso Medical Technologies is a Seattle-based medical device company that specializes in real-time localization technology for tumor tracking. Its proprietary system employs miniaturized implanted devices, known as Beacon electromagnetic transponders, to continuously and accurately monitor the location of tumors. This innovative approach aims to enhance the precision and management of radiation therapy delivery, particularly for body-wide cancers commonly treated with this method. The company's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed. Calypso Medical has established strategic partnerships with major industry players, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.

Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.

Avera Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes pharmaceutical compounds. The company develops gantacurium, a neuromuscular blocking agent for rapid and routine endotracheal intubation and skeletal muscle relaxation during surgery; AV810 for the treatment of overactive bladder and irritable bowel syndrome; and AV965 to treat cognitive impairment associated with schizophrenia and Alzheimer’s dementia. The company was founded in 2002 and is headquartered in San Diego, California.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Avera Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes pharmaceutical compounds. The company develops gantacurium, a neuromuscular blocking agent for rapid and routine endotracheal intubation and skeletal muscle relaxation during surgery; AV810 for the treatment of overactive bladder and irritable bowel syndrome; and AV965 to treat cognitive impairment associated with schizophrenia and Alzheimer’s dementia. The company was founded in 2002 and is headquartered in San Diego, California.

Reliant Pharmaceuticals is a company focused on developing and marketing cardiovascular pharmaceutical products. Established in 1999 and headquartered in Liberty Corner, New Jersey, it offers a range of medications designed to treat conditions such as hypertension, elevated cholesterol, and acid reflux disease. Its product portfolio includes Axid for acid reflux, InnoPran XL and DynaCirc CR for hypertension, Omacor for high triglycerides, and Rythmol SR. The company is involved in acquiring and developing branded pharmaceuticals, as well as potential products that are in mid- to late-stage clinical development. Reliant Pharmaceuticals distributes its products primarily to physicians in primary care, cardiovascular, and specialized medical fields.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.